U.S. Hotel and Resort REITs Stock News

Lee Enterprises stock barely flinched after earnings, ticking up less than 1% to about $8, even as the business delivered one of its cleanest profit turns in years. This is a company that came into this report with a weak recent share run over the past month, yet just posted Q3 basic earnings per share of $0.21 and net income of $4.7m on revenue of about $126m. The key development is sentiment catching up with a profit story that has been absent for a long time. The question now is whether...

Alta Equipment Group stock barely flinched after earnings, closing at US$7.50 for a 1.8% one day gain. That is a calm reaction for a company that just posted another quarterly loss. The market seems more interested in the story inside the margins than the red ink on the income statement. The headline this quarter is margin repair. Q2 revenue reached US$475.5m while the company reported a loss of US$8.2m. Yet adjusted earnings before interest, tax, depreciation and amortization landed at...

The market barely flinched on Enact Holdings, with the stock up just 0.6% to about $49, even as the company reported another quarter of high profitability. For a mortgage insurer, the headline is not the share move. It is a Q2 net profit of about $175 million on revenue of roughly $317 million, which keeps net margins above 50% and return on equity in the low teens. That quiet price reaction sets up a clear question for investors: Is this calm a sign of rational cool heads, or a market...

The Chemours Company recently reported past second-quarter 2026 results showing sales of US$1,591 million and a net loss of US$274 million, and also issued updated guidance calling for 2026 net sales to grow 1% to 5% over 2025 with a full-year net loss of US$255 million to US$230 million. At the same time, Chemours’ board declared a third-quarter 2026 cash dividend of US$0.0875 per share, underscoring management’s focus on shareholder returns despite ongoing losses and the CEO’s emphasis on...

Molson Coors Beverage shares were up 2.3% today and have gained around 12% over the past month. The market liked what it saw on the surface. Revenue for the June quarter came in at US$3.10b and basic earnings per share landed at US$1.24. For a brewer that has been loss making over the last twelve months and is carrying meaningful debt, the real story now is whether this quarter marks the start of a profit rebuild that can eventually support that dividend and narrow the gap between price and...

American Healthcare REIT stock jumped 3.7% to US$56.74 after the Q2 release, a quick reward for holders who had already seen a roughly 10% gain over the past three months. The headline is not the share price. It is cash generation. Normalized funds from operations, or FFO, came in at US$0.54 per diluted share and management lifted full year FFO guidance to US$2.15 to US$2.19. That move in guidance, backed by 13.2% same store net operating income growth, is what matters for anyone thinking...

The market barely blinked at Saul Centers, with the stock up just 0.6% to about US$34 after the Q2 release. For a retail focused real estate investment trust that often trades on its income story, such a muted move hides the real tension. Funds From Operations, the key cash flow yardstick for REITs, now sits at about US$96.7m over the past year, while reported earnings margins over that same period remain compressed. Coming into today, the stock had drifted lower over the past month. The...

Tucows stock jumped 11.4% to US$15.68 after its latest quarterly report, a sharp move for a company that many investors still file under “deep value telecom and internet infrastructure.” The headline is not a clean profit story. Revenue for Q2 2026 came in at US$100.6m while the company reported a basic loss per share of US$1.84. The core question now is whether that mix of growing top line and ongoing losses fits or breaks the long term thesis around low price to sales and a heavily burdened...

Collegium Pharmaceutical stock inched up 1.2% to US$29.47 after earnings, a muted move for a company that just swung from a Q1 profit to a Q2 loss. The market focused on the headline net loss of US$15.1m, yet the more important story for you is the margin squeeze behind that number. Revenue in Q2 came in at US$199.9m, supported by the expanding attention deficit hyperactivity disorder portfolio. However, acquisition costs and authorized generics in pain treatments pressured profitability. The...

Payoneer Global’s stock barely moved on the earnings release, slipping less than 1% and sitting near US$7.10. The calm price masks a sharper story. The market is staring at a payments platform that just swung from a US$19.6 million profit in Q1 to a small loss in Q2, while still trading on a rich P/E of 47.8x. That mix of profit pressure and premium valuation is the core tension. The following sections examine whether this quarter’s margin squeeze helps explain the muted reaction, or whether...

vTv Therapeutics stock inched up 2.2% to US$35.37 heading into the first full trading day after earnings, even as the headline told a harsher story. Q2 flipped sharply back into loss making territory, with basic earnings per share swinging to a loss of US$1.05 and revenue dropping to zero after a one off US$36.84m in Q1. The short term relief rally sits against a tougher long term picture. vTv Therapeutics remains unprofitable over the past year. Is vTv Therapeutics trading at a genuine...

Central banks are signalling that policy rates may stay higher for longer as inflation pressures, including energy costs, remain in focus. That keeps cheap capital scarce and puts extra attention on technologies that could reshape computing efficiency, such as quantum computing. This article highlights three stocks from our Quantum Computing Stocks screener that show how different parts of the quantum value chain are trying to position for this backdrop. The three stocks covered next are just...

Globalstar barely moved in regular trading, with the stock edging up just 0.2% despite another loss on the bottom line. That muted reaction hides the real tension in this quarter. The story is not about small price swings or near term revenue noise. The story is the growing strain between a rich valuation and ongoing losses. Globalstar generated US$64.8m in Q2 revenue yet still reported a net loss of US$26.5m and a loss per share of US$0.21. With the stock trading on a P/S multiple that far...

Celsius Holdings came into this print with a bruised stock chart and a hyped growth story. Over the past three months the share price fell about 14%, yet after Q2 results the stock ripped about 17% higher to US$27.77 in a single session. That move flags how quickly sentiment can flip when numbers reset the narrative. The headline this quarter is profit pressure in the middle of solid top line progress. Revenue reached US$817.9m while basic earnings per share dropped to US$0.14 and net income...

Kelly Services stock slipped 2.8% to US$15.19 in the first trading session after earnings, even though the headline numbers pointed to a cleaner quarter than many investors had grown used to. The company posted Q2 revenue of about US$1.04b and returned to positive earnings per share of roughly US$0.33, with adjusted earnings before interest, tax, depreciation and amortization margin improving to 3%. For a staffing and workforce solutions stock that has been wrestling with losses and modest...

The market reacted positively to DraftKings on the headline, with the stock jumping about 8% to roughly $24 after earnings, even though the quarter swung back to a loss. That move rests on one core idea: investors are treating adjusted EBITDA of $115 million and reaffirmed 2026 guidance of $700 million to $900 million as evidence that the profit story remains intact. Coming into the release, the stock had cooled over the past month and quarter. Today is a sentiment reset built around one key...

Evergy stock barely moved after earnings, ticking up about 0.4% to US$83.38, which suggests the market viewed the report as business as usual. The numbers, however, indicate a more detailed picture. Quarterly earnings per share were about US$0.93 and adjusted earnings per share for the quarter came in at US$0.88, with management reaffirming a US$4.24 full-year adjusted earnings midpoint. That calm price reaction sits alongside a broader consideration. Evergy is trading near 21x earnings while...

Lineage Cell Therapeutics slipped 2.7% to about US$1.10 after its second quarter report, a muted move for a stock that has already shed close to 20% over the past three months. The headline in this print is not the top line. It is the sharp squeeze between a tiny US$1.1 million in quarterly revenue and a much heavier cost base, even though this quarter showed a US$1.5 million net income on paper. That profit figure rests largely on noncash warrant revaluation. The key consideration for long...

Haemonetics stock came into this quarter on a tear, with shares up almost 60% over the past three months and another 3.3% added today. That kind of move sets a high bar. The headline from the print is straightforward: revenue reached US$339.4m and adjusted earnings per share landed at US$1.14, while management pushed full year revenue guidance higher. For a company long viewed as a steady blood and plasma technology compounder, the real story this quarter is not a growth scare. Instead, it is...

NexPoint Real Estate Finance stock added 3.3% today to close at US$18.17, capping a strong 30 day run. However, the real story sits in the cash engine behind that move. The headline from this mortgage REIT’s quarter is not basic earnings per share. It is that cash available for distribution covered the US$0.50 dividend at 1.16x, and the board still signed off on another US$0.50 for Q3. Short term traders are reacting to the bounce. Longer term investors are likely to focus on how this...

Tarsus Pharmaceuticals stock slipped 0.8% to US$64.79 after the Q2 print, a muted reaction for a company that just posted US$173.9m in quarterly net product sales from a single flagship drug. The market focused on another quarterly loss and the near term hit from heavier research and development spending. In the longer term, the story sits in a different place. Revenue over the past year has reached US$606.3m, management has raised 2026 sales guidance for XDEMVY, and the balance sheet held...

Amphastar Pharmaceuticals stock closed up 4.9% at US$20.78, yet the real story sits behind that modest relief rally. Q2 delivered a sharp earnings snapback, with basic earnings per share at US$0.70 on revenue of US$183.9m, and management leaning into share repurchases with about US$45m bought back in the quarter. The market is reacting to the quarter in front of it. The bigger question for you is how this drug maker’s margin pressure, earnings outlook and wide gap to the referenced fair value...

Palantir Technologies (PLTR) is back in focus after its second quarter 2026 earnings report, which showed revenue of US$1.94b and net income of US$1.06b, alongside a sharp stock move. See our latest analysis for Palantir Technologies. The second quarter results and raised 2026 guidance have come alongside a sharp shift in sentiment toward Palantir Technologies, with a 10.32% 1 day share price return and a 39.78% 7 day share price return, while the 1 year total shareholder return is down 8%...

OmniAb walked into this quarter with a reputation as a high multiple, high promise antibody discovery platform, and the stock has just been reminded of that. Shares jumped 37.5% to US$3.08 after the Q2 2026 release, a sharp move for a company that still reports losses but just posted US$13.4m in revenue and a much smaller net loss of US$5.9m. The real story for OmniAb this time is the earnings trend. Losses are shrinking while milestone revenue from partner drugs advancing in the clinic does...